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Abstract: In many neurological disorders strategies for a specific delivery of a biological 
activity from the periphery to the central nervous system (CNS) remains a considerable 
challenge for successful therapy. Reporter assays have established that the non-toxic 
C-fragment of tetanus toxin (TTC), provided either as protein or encoded by non-viral 
naked DNA plasmid, binds pre-synaptic motor neuron terminals and can facilitate the 
retrograde axonal transport of desired therapeutic molecules to the CNS. Alleviated 
symptoms in animal models of neurological diseases upon delivery of therapeutic 
molecules offer a hopeful prospect for TTC therapy. This review focuses on what has been 
learned on TTC-mediated neuronal targeting, and discusses the recent discovery that, 
instead of being merely a carrier molecule, TTC itself may well harbor neuroprotective 
properties. 
Keywords:  tetanus toxin C-fragment; therapeutic molecules; gene therapy; retrograde 
transport; neurodegenerative disease; motor neuron disease 
 
1. Introduction  
1.1. Overview 
Neurodegenerative disorders are a group of pathological conditions that typically originate from 
progressive dysfunction and loss of neurons or synaptic contacts in defined areas of the nervous 
system. For example, Alzheimer’s, Parkinson’s and Huntington’s diseases affect distinct parts of the 
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central nervous system (CNS), whereas motor neuron diseases such as Amyotrophic lateral 
sclerosis (ALS) and spinal muscular atrophy (SMA) initiate peripherally by a loss of motor neural 
connection with the muscle. Although major steps in understanding the pathology and molecular 
mechanisms underlining these disorders have been taken, effective treatment has only been described 
in few. Besides the obvious task of finding the appropriate molecules or interventions with beneficial 
effect, one of the greatest challenges in development of treatments for neurodegenerative conditions 
relies on the fact that systemic delivery of potential therapeutics, such as growth factors or 
neurotrophins, may be ineffective due to short half-life and low bioavailability at the target tissue, as 
well as having potentially hazardous side effects [1,2]. The existence of blood-brain-barrier (BBB) 
normally precludes direct vascular delivery of large molecules to the CNS. It is, therefore, worthwhile 
to look for delivery methods that are minimally invasive and can be administered to the peripheral 
tissues but which may then specifically bear the therapeutic effect via distal neurons into the CNS. 
Traditionally these methods have relied on the ability of neurotropic viruses to serve as carriers, 
because they are taken up by the nerve termini and transported to the soma. However, although these 
may be resolved in the future, viral gene therapy may still involve complications, such as   
cargo molecule size restriction, as well as potential hazards related to genomic integration, that need to 
be considered [3].  
Non-toxic tetanus toxin C-fragment (TTC) has been exploited as a molecular tool to specifically 
target motor neurons and has greatly facilitated studies of neuronal processes such as endocytosis, 
synaptic sorting and retrograde transport in vitro and in vivo [4]. Molecules may be fused with TTC 
without apparent loss of biological activity, which can provide valuable therapeutic tools for fighting 
neurodegeneration. Furthermore, recent evidence also suggests that TTC may harbor therapeutic 
properties itself [5]. This review focuses on what has been learned about TTC based therapies with 
special emphasis on motor neuron diseases.  Besides the previously mentioned neurodegenerative 
conditions, the design of enzyme-replacement therapies for lysosomal storage disorders with 
neurological involvement may benefit from the trans-synaptic properties of TTC. 
1.2. Tetanus Toxin  
Tetanus neurotoxin (TeNT, also known as TeTx or tetanospasmin) is a protein produced by 
Clostridium tetani, an anaerobic bacterium whose spores are commonly found in soil and animal 
waste. TeNT is a causative agent of tetanus, a potentially fatal condition that affects the nervous 
system and is characterized by painful, uncontrolled muscle contractions [6]. It is synthesized as a 
single polypeptide and is post-translationally modified to produce light (L) and heavy (H) chains 
linked by disulfide bonds [7]. Although the binding and internalization of the toxin has not been 
systematically studied in different populations of neurons, TeNT shows remarkable affinity and 
specificity to neuronal terminals. It is internalized primarily by the motor neurons at the neuromuscular 
junction (NMJ) where it enters the axonal retrograde transport pathway and is subsequently transported 
to the neuronal soma in the CNS [4,8]. The L chain harbors a neurotoxic zinc metalloprotease activity 
which targets integral membrane protein VAMP/synaptobrevin, a synaptic vesicle-associated 
membrane protein required for neurotransmitter release [9,10]. Proteolytic cleavage of 
VAMP/synaptobrevin in the synapses of inhibitory interneurons (Renshaw cells) by the TeNT L chain, Toxins 2010, 2  
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prevents the release of the neurotransmitters γ-aminobutyric acid (GABA) and glycine into the 
synaptic cleft, and results in sustained motor neuron excitation causing tetanic spasms. The H chain 
consists of two non-toxic fragments, HN and HC. The HN is thought to facilitate the translocation of the 
toxic L chain from endosomal compartment to the cytosol or otherwise modulate its trafficking 
route  [11]. The 50 kDa carboxy-terminal HC (hereafter called TTC) is required for neuronal cell 
binding and retrograde transport [12–15].  
Neuronal transport [16], which normally carries enzymes and cellular organelles from distal axon 
terminals to the neuronal cell bodies, can be exploited by the TeNT to penetrate the BBB and to enter 
the CNS [8]. TeNT toxicity relies on the presence of L chain, but its targeting to the neuronal synapses 
is dependent solely on non-toxic TTC [15]. The internalization of both holotoxin and TTC initiates by 
interaction of TTC with neural gangliosides and specific (mainly uncharacterized) proteins on 
axolemmal infoldings associated with lipid microdomains of neuronal surface [17–22]. The binding is 
followed by clathrin-dependent endocytosis [23,24] and intracellular trafficking inside neutral 
endocytic vesicles [25]. The vesicles move retroaxonally towards the motor neuron cell body mainly 
using fast axonal transport that relies on both actin microfilaments and microtubule-interacting motor 
proteins [4,26,27]. From the soma, TTC may further reach the dendrites and can subsequently be 
transported to interneurons that synaptically connect with motor neurons [13,28]. 
Early studies of transsynaptic passage of radioactively labeled TeNT in vivo were limited by 
development of clinical tetanus and rapid death of the experimental animals [29,30]. Separation of 
toxicity and targeting functions by enzymatic cleavage or molecular cloning methods has allowed 
in vivo investigation of TTC internalization by neurons and their retrograde transport from the 
periphery to the central nervous system. Indeed, TTC has become an important tool to investigate 
neuronal physiology in a normal context and in conditions where neuronal function is affected 
by a disorder.  
2. TTC as a Neuronal Retrograde Tracer and Carrier of Therapeutic Molecules 
Several molecules, including reporter genes and potential therapeutic molecules, have been 
successfully transported into neurons by coupling them with TTC (Table 1). The use of TTC as a 
carrier for therapeutic molecules to the CNS was first proposed by Bizzini and coworkers [12,17]. 
Since then, even large 150 kDa proteins have been shown to be efficiently internalized by 
TTC-mediated endocytosis. Here, we will first describe the various marker genes used to study TTC 
targeting function, neuroanatomy and physiology, and then proceed to the therapeutic approaches 
achieved by chimeric TTC constructs (protein or gene therapy) in vitro and in animal models of 
neurodegenerative diseases.  
2.1. TTC as a Tracer for Neuroanatomy and Cellular Physiology 
Natural capability of TTC to employ neuronal retrograde transport machinery and transcytose to 
connecting higher order neurons has been exploited to investigate neuroanatomy and to trace 
physiological and molecular mechanisms of retrograde axonal trafficking. The applied methods 
include chemical or genetic conjugation of TTC to a histochemically of fluorescently detectable 
reporter molecules, as well as direct labelling of TTC with fluorochromes. Fluorochrome-labelled or Toxins 2010, 2  
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chemically conjugated TTC-tracers may be delivered as protein injection. On the other hand, genetic 
fusion proteins have been administered either as a recombinant protein or as non-viral “naked DNA” 
plasmid [31]. In the latter method, the TTC hybrid-encoding plasmid is directly injected into the tissue 
where it is taken up by cells, transcribed as mRNA, translated to protein and secreted. Various routes 
of administration have been used in vivo, the most common being intramuscular injection. 
More than 20 years ago it was shown that intramuscular administration of recombinant TTC 
conjugated with horse radish peroxidase (HRP-TTC) [13] could result in internalization of HRP 
activity by motor neurons and its axonal transport within cytoplasmic vesicles. Furthermore, 
TTC-conjugation was shown to radically improve neuronal internalization of even large proteins, such 
as human IgG [32] or glucose oxidase [33], and to enable neuronal delivery of DNA coupled to the 
TTC with polylysine bridge [34]. Similar findings were found later using TTC coupled with 
beta-galactosidase (β-gal-TTC) delivered intramuscularly either as β-gal-TTC fusion protein [35–37] 
or as direct “naked DNA” plasmid injection in Xenopus [38] and in mice [37]. It was also 
demonstrated that β-gal-TTC is transneuronally transported to second and higher-order interconnected 
neurons [36] and that the transport to motor neurons was dependent on neuronal activity [39]. Block of 
neuronal action potentials by surgical denervation or tetrodotoxin, inhibited the transmission of the 
tracer in the NMJ, whereas blocking acetylcholine stimulation of the post-synaptic muscle by 
botulinum toxin, which leaves nerve function intact, did not affect the transmission.  
To facilitate direct microscopic visualization, fusion protein of TTC and green fluorescent protein 
(TTC-GFP) has been successfully delivered to the neurons by using adenoviral vectors or intracerebral 
crafting of transfected neural cells [40], by transgenic methods, in mice expressing GFP-TTC hybrid 
gene under general and cell-type-specific promoters [41,42] as well as by direct intramuscular 
injection fusion protein [24,43,44]. Because the intensity of the signal is effectively diluted when TTC 
tracer proceeds towards CNS, the detection of fluorescently labeled tracer becomes progressively more 
challenged. For example, Perreault and coworkers [43] used intramuscular injection of TTC-GPF to 
trace central connections from a single hind-limb muscle in neonatal mice. Although spinal motor 
neurons were effectively labeled, the labeling of more central pre-motor neurons was restricted to the 
synaptic terminals and lacked signal in the cell soma. In another study, however, GFP-TTC fusion 
protein was readily detected in the soma of inhibitory interneurons [44] and the reason for this 
discrepancy remains unclear. Until the problems related to the weak signal have been resolved, the fine 
details of the higher order neuroanatomical connections are likely to rely on transgenic animals where 
high and more precise expression may be achieved, and even in this case anti-GFP antibody staining 
instead of direct fluorescent detection is usually required [41,42]. In the transgenic mice used by 
Makos and coworkers [41], the GFP-TTC tracer was coupled with an internal ribosome entry site 
driving the expression of β-gal, which provides an additional advantage as the cells of origin   
(β-gal positive) may be easily identified from those where GFP-signal has been acquired by 
transneuronal transport (β-gal negative). So far, GFP-TTC (or TTC-GFP) transgenics have been used 
successfully to trace neuronal connections in hippocampus [41], circuits that control locomotion and 
posture [44] and those that regulate sleep/wakefulness state [42]. Toxins 2010, 2  
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Table 1. List of proteins conjugated to TTC, their conjugation method and models that 
have been used to study neuronal internalization in vivo and in vitro. 
Construct  Fused Protein  Method 
1 
Model (Administration); 
in vitro Model 
2 
Reported 
Location/Transport, 
(effect) 
References 
3
TTC-HRP 
Horse radish 
peroxidase 
CC, RPb   Mouse (IM, IP, IC)  
Coated vesicles, 
endosomes 
[13,58] 
TTC-HRP-hIgG 
Horse radish 
peroxidase-hIgG  
CC   Mouse (IM, IP)   MNs, CNS  [32] 
GO-TTC  Glucose oxidase  CC  Mouse (IM)   MN terminals, CNS  [33] 
β-Gal-TTC  β -galactosidase  RPb, ND 
Mouse (IM), rat (IM), 
Xenopus (IM)  
NMJs, MNs, CNS, 2nd and 
higher order neurons 
[35–39] 
GFP-TTC 
Green fluorescent 
protein  
RP, ND, 
TG 
Mouse (IM, IC); mouse and rat 
primary culture neurons, rat 
spinal cord MNs 
MN terminals, coated 
vesicles, endosomes, 2nd 
and higher order neurons 
[24,35, 
40–44,68,99]
TTC-HEXA 
β -N-
acetylhexosaminid
ase-A 
CC  
Rat primary culture neurons, 
feline GM2 gangliosidosis 
neuronal culture 
Endosomes, (enhances 
GM2 degradation - 
secondary lysosomes?) 
[48] 
SOD1-TTC 
Cu/Zn superoxide 
dismutase  
RPb 
Mouse (IM, IC); murine 
neuroblastoma hybrid cell line
Intra-cytoplasmic vesicles, 
MNs, CNS, (no protection 
from oxidative injury) 
[52–53, 
59,63] 
SMN1-TTC 
Survival motor 
neuron 1  
RPb  Rat primary culture neurons  
Neuronal surface, not 
internalized 
[63] 
CT1-TTC Cardiotrophin-1    RPb 
Mouse and rat primary culture 
neurons, rat spinal cord MNs 
Intra-cytoplasmic vesicles, 
synaptic contacts, (induces 
CT1-dependent cellular 
processes) 
[68] 
Bcl-xL-GFP-
TTC 
B-cell lymphoma-
extra large  
RPb 
Rat spinal cord MNs, dorsal 
root ganglion neurons 
Internalized and transported 
to soma, (protects from 
apoptosis) 
[72] 
IGF-1-TTC 
Insulin-like 
growth factor 1  
RPb, RPi 
Mouse, SOD1G93A mouse 
(IM, IT); mouse spinal cord 
MNs 
Intra-cytoplasmic vesicles, 
MNs, CNS, (prevents 
muscle force decline with 
age, fails to improve 
SOD1G93A survival) 
[79–81] 
GDNF-TTC 
Glial derived 
neurotrophic 
factor  
CC, RPb, 
RPi 
Mouse (IM, IT), SOD1G93A 
mouse (IM); mouse neuronal 
cell lines, rat axotomized MNs 
MNs, CNS, (protect 
axotomized MNs, prolongs 
SOD1G93A survival) 
[95–97] 
BDNF-TTC 
Brain derived 
neurotrophic 
factor  
RPb 
Mouse cortical neurons and 
neuroblastoma cell line 
Internalized, (induces Akt 
pathway, inhibits 
apoptosis) 
[98] 
1 CC= chemical cross-link, RPb= bacterial recombinant protein, RPi= insect recombinant protein,   
ND= naked DNA plasmid, TG= transgenic animal. 
2 IM= intramuscular injection, IP= intraperitoneal 
injection, IT= intrathecal injection, IC= intracerebral injection, MNs= motor neurons. 
3 Please note that the 
references are given in the order that they appear in the text. 
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As for neuroanatomy, TTC has served as an important tool to investigate mechanistic aspects of 
neuronal traffic. Using paramagnetic iron beads coupled with TTC, it was shown [26] that small 
GTPase Rab7 plays an essential role as a functional marker of axonal retrograde carriers which 
transport neurotrophins and their receptors, such as brain-derived neurotrophic factor (BDNF), its 
receptor TrkB and the p75 neurotrophin receptor (p75NTR). These factors regulate synaptic strength 
and plasticity in mammalian nervous system as well as promote growth, maintenance and survival of 
their target neurons. This observation is interesting because it implicates that TTC exploits machinery 
that naturally occurs in nerve cells, and, therefore, may provide a more reliable delivery method for 
therapies aiming to increase trophic support for the neurons in neuronal diseases. Additionally, when 
coupled with visible markers such as fluorochromes, TTC may provide a useful tool for studies of 
axonal transport mechanisms in development and disease. This is of particular interest for those 
studying motor neuron diseases, since mutations perturbing retrograde transport have been shown to 
mimic hallmarks of human pathology [27,45]. Recently it has been demonstrated [46] that TTC can be 
fluorescently labeled without loss of its biological potency or immunoreactivity. TTC labeled with 
fluorochromes could be detected with whole-body molecular imaging technology allowing 
determination of in vivo retrograde transport to the CNS after intramuscular injection, as well as   
ex vivo histological mapping of the fate and transport rate of the tracer. Because of the non-toxicity and 
non-invasive administration, tracers of this class may become important agents for neurography in 
humans. For example, they may ease neuronal detection in complicated surgical procedures, aid 
visualization of neuronal circuits after injury, or function as a marker to evaluate therapeutic effects of 
neuroprotective of neurotrophic treatments. 
Less is known about the mechanism of how TTC and its fusion variants are transported from the 
motor neuron dendrites to the more central interconnected axons. The existing data suggests that the 
internalization is mechanistically different in the presynaptic terminals of the NMJs and in those of 
centrally located axonal projections, such as inhibitory interneurons [10]. For example, in cultured 
hippocampal neurons TeNT is internalized by synaptic vesicle recycling, i.e., in a depolarization- and 
calcium-dependent manner [47]; whereas in motor nerve endings the internalization is 
clathrin-dependent [23] and is not significantly altered by depolarizing conditions and is little affected 
by calcium [24]. The question also remains if intracellular trafficking of TTC molecules in the central 
interconnected neurons relies on similar retrograde transport apparatus as in the primary motor neurons 
[4,23,25,26]. These potential differences require further elucidation and are likely to be clarified when 
more sensitive methods for centrally interconnected neurons are developed. It is also worth mentioning 
that TTC may not work well as a tracer in neonatal animals where NMJs are not fully mature [43]. 
However, the potential of TTC to mediate retrograde transport to the CNS in adult animals is clearly 
established and has served as a starting point for studies investigating TTC-dependent trafficking of 
potentially therapeutic enzymes to the CNS. 
2.2. TTC-mediated Neuronal Targeting of Metabolic Enzymes  
Lost or altered metabolic enzyme activity underlies many neurodegenerative and neuromuscular 
diseases, including classical MNDs, some forms of peripheral neuropathy and neuronal lysosome Toxins 2010, 2  
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storage diseases. When a single gene product is affected negatively by the condition, enzyme 
replacement therapy may offer a promising approach to compensate insufficient biological activity. 
Tay Sachs disease (TSD) is an autosomal recessive human GM2 gangliosidosis characterized by 
lipid accumulation in the lysosomes of the nervous tissue and progressive deterioration of the brain and 
the spinal cord. TSD is caused by inactivating mutations in the gene for lysosomal GM2 
ganglioside-degrading enzyme beta-hexosaminidase (HEXA) and represents an attractive target for 
enzyme replacement therapy. Human placental HEXA conjugated with TTC (but not HEXA alone) 
was found to be efficiently internalized by rat brain cells in vitro [48]. Furthermore, HEXA uptake was 
not enhanced by the presence of free TTC indicating the dependence on covalent linkage between the 
therapeutic molecule and the TTC. In cerebral cortex cell cultures from cat model of TSD, 
TTC-HEXA conjugates were able to reduce the accumulation of lysosomal lipids indicating that 
TTC-conjugation did not interfere with the enzymatic activity of HEXA. This also suggests that a 
significant part of the TTC-HEXA reached secondary lysosomes where GM2 gangliosides 
preferentially accumulate in these cells. While these results are promising with respect to non-viral 
treatment of lysosomal storage diseases with neurological involvement, they still await verification as 
a therapeutic tool in described animal models [49]. 
Cu/Zn superoxide dismutase (SOD1) is a cytosolic enzyme that converts superoxide radicals to 
molecular oxygen and hydrogen peroxide and thus protects cells from oxidative stress. SOD1 is 
mutated in 20% of the familial ALS patients [50] and increased SOD1 activity is neuroprotective in a 
mouse model of chemically induced Parkinson’s disease [51]. Recombinant fusion proteins of human 
SOD1 and TTC (SOD1-TTC), but not SOD1 alone, were shown to be efficiently internalized by the 
motor neurons and transsynaptically transported after intramuscular injections in mice [52]. Post 
injection, the molar excess of SOD1-TTC to the endogenous mouse SOD1 was estimated to be six-fold 
in motor neurons indicating efficient internalization. However, the activity of SOD1 in the fusion 
constructs was negatively affected, and it is not known to which subcellular location SOD1-TTC 
transported (endosomal or cytosolic). In vitro, SOD1-TTC molecules are ineffective in protection of 
cells from starvation-induced oxidative stress, possibly due to their location in the vesicles [53]. 
Although SOD1-TTC remains a potentially attractive neurotropic antioxidant, its beneficial in vivo 
effects have not yet been reported. Because SOD1 mutants associated with ALS are not hypomorphic 
but instead gain-of-function, wild-type SOD1 expression in ALS may not be beneficial at least in 
familial ALS [54,55]. However, SOD1 expression has been shown to be beneficial for recovery from 
spinal cord injury and ischemia in rats [56,57] and, therefore, may harbor alternative therapeutic use in 
post-traumatic treatment. 
Although TeNT entry to the CNS is thought to be primarily mediated by binding to the motor 
neuron terminals at the NMJ, all neurons seem to be capable of binding both TeNT and TTC. 
Recombinant SOD1-TTC fusion protein used for a previous study [52] was also the first one used to 
evaluate the distribution and uptake of TTC-coupled protein after direct intracerebral injection [58] and 
cerebrospinal fluid infusion [59]. Although the metabolic effects of the SOD1 were not evaluated in 
the first study, TTC-SOD1 fusion protein showed vastly superior retention within brain tissue than 
SOD1 alone (or bovine serum albumin), and were distributed in synaptic and endosomal pattern 
suggesting retrograde transport [58]. In the latter study, it was demonstrated that TTC improved the 
stability of the SOD1, consistent with internalization by neurons. The delivered fusion protein was Toxins 2010, 2  
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structurally intact and retained its SOD1 activity [59]. This suggests that, besides well-documented 
intramuscular administration, TTC may be suitable for intracerebroventricular or direct brain 
administration when less invasive methods are considered inefficient. This could be the case where the 
target neurons do not have projections outside the BBB or where specific centrally located parts of the 
brain are affected. However, the possibility that SOD1-TTC treatment is ineffective exists if, like 
in vitro, it is not released from the endosomal containment [53]. 
Spinal muscular atrophy (SMA), the most common genetic cause of infant mortality [60], is a 
recessive paralytic disease that results in selective loss of lower motor neurons. It is caused by 
mutations that reduce the amount of survival of motor neuron 1 (SMN1) [61], a protein that 
orchestrates the assembly of multiple protein-RNA complexes and contributes directly to mRNA 
splicing [62]. Increased levels of neuronal SMN1 may be beneficial for SMA patients, leading Francis 
and coworkers [63] to study the binding and internalization of genetic fusion of SMN1 and TTC 
(SMN1-TTC) in neuronal cell cultures. Because it is not clear if the passenger proteins may escape 
from the vesicular compartment after internalization by neurons, the authors included modified piece 
of diphtheria toxin to the SMN1-TTC molecule which they predicted to facilitate the export from the 
endosomal compartment to the cytosol. Unfortunately, collective evidence from these studies 
suggested that although all domains of the fusion protein retained their activity the internalization was 
prevented by the SMN1 domain. Importantly, this study implicated that the properties of the passenger 
molecule may negatively affect the internalization of the fusion protein. 
2.3. TTC-mediated Delivery of Survival Factors, Growth Factors and Neurotrophins  
Neuronal survival is dependent on constant exposure to neurotrophins which also mediate 
differentiation, growth, and apoptosis of neurons by binding to two types of cell surface receptors, the 
Trk tyrosine kinases and the p75NTR [45,64]. As mentioned earlier, TTC is transported inside the 
motor neurons in compartments including neurotrophins and their receptors [26], and may therefore 
serve as a “natural” signal to potentiate targeting of factors expected to enhance neuronal viability by 
inducing survival signals and by counteracting apoptotic cell death.  
Cardiotrophin-1 (CT1) is a cytokine of IL6 family that can increase motor neuron survival in vitro 
and in vivo. CT1 improves motor function, increases survival and protects NMJs in progressive motor 
neuropathy (pmn) mice, after adenoviral or naked DNA mediated delivery [65,66]. Additionally, 
intramuscular administration of adenoviral vector-encoded CT1 has been shown to be beneficial in the 
mouse model of SMA [67]. However, serious pleiotrophic side effects resulting from the high-level 
systemic or muscle administration, such as weight loss and cardiac hypertrophy, would preclude the 
use of CT1 for molecular therapy in human patients. To circumvent this problem, more targeted 
delivery of this cytokine to the nervous system was studied [68]. Genetic fusion of CT1-TTC (which 
also included GFP for direct visualization) efficiently bound and was internalized rapidly by cerebral 
neurons and spinal cord motor neurons in vitro, whereas the glia, hepatocytes or cardiomyocytes did 
not bind or uptake the recombinant protein. CT1-TTC promoted motor neuron survival in a 
dose-dependent manner in vitro and induced typical CT1 responses, including IL-6 secretion and 
transcriptional activation of its known target genes. This implies that TTC does not interfere with the 
endogenous function of the cytokine and that CT1-TTC could serve as a candidate for in vivo studies. Toxins 2010, 2  
 
 
2630
TTC-conjugation may be particularly relevant to CT-1 since, unlike some other neurotrophic factors, it 
is not transported to neuronal dendrites and may be subjected to rapid lysosomal degradation [69], both 
of which could be positively modulated by TTC domain.  
Apoptosis plays a key role in death of neurons in neurodegenerative diseases [70]. Findings from 
patients and animal models of such diseases indicate strong contribution by altered mitochondrial 
metabolism, and respiratory chain-deficient cells are more likely to undergo apoptosis. Bcl-xL is an 
antiapoptotic protein whose expression is decreased in neurodegenerative conditions such as ALS [71]. 
Bcl-xL-TTC fusion protein (which also contained GFP for detection) was found to be specifically 
taken up by rat spinal cord motor neurons and dorsal root ganglion neurons and was transported to the 
cell bodies in vitro [72]. Importantly, fusion protein application improved cell survival and decreased 
apoptosis in response to glutamate-mediated toxicity. In the same study, it was reported that the 
positioning on the TTC to the carboxy-terminal side of the Bcl-xL-TTC fusion protein was an absolute 
requirement for internalization. Although Bcl-xl-TTC remains a promising candidate for exploration in 
animal models of neurodegenerative disease, studies investigating its effect in vivo are still pending. 
Several neurotrophic factors and growth factors have been suggested for the treatment of motor 
neuron diseases.
 In ALS patients, however, the repeated subcutaneous injection
 of these factors as 
recombinant proteins may be complicated by
 their systemic toxicity due to their tropism to a variety of 
tissues and a poor bioavailability at the motor neuron terminals [73–75]. The latter may be affected by 
inefficient binding/internalization or short half-life of these factors.  
Insulin-like growth factor 1 (IGF-1) promotes growth of both skeletal muscles and motor neurons, 
and muscle-specific expression of IGF-1 can provide trophic support to the motor neurons. IGF-1 has 
been shown to decrease disease pathology and progression in animal models of ALS [76] and spinal 
and bulbar muscular atrophy [77], as well as alleviate symptoms in a mouse model of diabetic 
peripheral neuropathy [78]. Fusion protein consisting of IGF1 and TTC domain (IGF1-TTC) retain 
biological activity of both domains as demonstrated by increased mitogenic activity in L6 muscle cells 
as well as by in vitro and in vivo neuronal retrograde transport [79]. Furthermore, intramuscular 
administration of IGF1-TTC prevented specific force decline in aging mouse muscles, as well as 
attenuated age-related denervation of fast muscle NMJs [79,80]. However, although IGF-1 delivery to 
the spinal cord was massively improved by TTC domain, and it retained significant level of IGF-1 
activity as measured by Akt phosphorylation, no positive effect could be demonstrated on the course of 
the disease in a mouse model of ALS either by intrathecal of intramuscular delivery [81]. This is 
consistent with previous demonstration that muscle-specific or CNS over expression of IGF-1 is not 
beneficial in ALS mice [82], suggesting that central or retrograde delivery of IGF-1 does not improve 
ALS symptoms. The efficacy of IGF1-TTC in other forms of disease where IGF-1 is expected to be 
beneficial is currently unknown. 
Glial cell-derived neurotrophic factor (GDNF) potently promotes the survival, proliferation and 
differentiation of various types of neurons, including motor neurons [83–87]. Because penetration of 
GDNF into brain tissue from either the blood or the cerebro-spinal fluid is limited, direct delivery to 
the brain has been widely used despite being a highly invasive procedure. In rodent and primate 
models of Parkinson’s disease, GDNF is neuroprotective [88,89] but a number of clinical trials in 
which GDNF has been directly delivered to the brain of Parkinson’s disease patients have produced 
mixed, inconclusive results [90–92]. In a mouse model of ALS that expresses human SOD1 mutant Toxins 2010, 2  
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(G93A), skeletal muscle-specific expression of GNDF increased survival of the spinal motor neurons, 
delayed the onset and progression of the disease, as well as increased life span [93]. However, 
expression in the CNS (astrocytes) carried out in the same study failed to demonstrate any protective 
effects, suggesting that retrograde delivery to the neurons was required for the therapeutic effects. In a 
rat model of ALS (SOD1-G93A), human neural stem cells genetically modified to release GDNF and 
surgically transplanted into CNS protected motor neurons but not their projections to the muscle [94]. 
In mice, the delivery of GDNF to the spinal motor neurons and spinal cord is improved by conjugation 
with TTC after intramuscular of intrathecal administration and, in both cases, the biological activity of 
GDNF is maintained [95,96]. GDNF-TTC was also shown to increase survival after experimentally 
induced damage rat spinal cord motor neurons [95]. Importantly, Ciriza and coworkers [97] 
demonstrated that genetically fused GDNF-TTC is antiapoptotic and induces Akt kinase survival 
pathway in cultured neurons, as well as improves activity and prolongs survival of the ALS 
(SOD1-G93A) mice. Although the effect of GDNF or TTC alone on lifespan was not demonstrated, 
these data suggest that intramuscular injection of GDNF-TTC may be beneficial at least in 
“dying-back” axonopathies such as ALS. 
Brain derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors 
related to the canonical nerve growth factor, NGF. Genetic fusion of BDNF and TTC (BDNF-TTC) 
can induce neuronal survival Akt kinase pathway in mouse cortical culture neurons and inhibit 
apoptosis in mouse neuroblastoma cells [98]. Although protection from apoptosis was virtually 
identical compared with BDNF alone (but higher than TTC alone), mildly reduced potency or 
BDNF-TTC to activate Akt pathway may indicate negative effect on BDNF function by TTC. An 
alternative hypothesis is that TTC harbors antiapoptotic properties, which are potentiated by BDNF 
fusion. In this case, enhanced function of BDNF-TTC compared with TTC alone may derive from the 
fact that BDNF is able to promote TTC-internalization to the neurons in mature mouse motor neuron 
terminals [99]. Indeed, recent studies suggest that TTC itself harbors neuroprotective properties which 
are discussed in detail below. 
3. Neuroprotective Properties of TTC Alone 
Signaling through phosphatidylinositol 3-kinase (PI-3K), followed by PI-3K-mediated activation of 
serine/threonine kinase Akt is the key regulator of neuronal survival [64,100,101]. Additionally, 
protection from injury and cellular toxicity seems to be controlled by MAP kinase/extracellular 
signal-regulated kinase (MAPK/ERK) pathway [64]. Neuroprotection by neurotrophic factors derives 
from their potential to induce these pathways through their tyrosine kinase (Trk) receptors. 
Binding of TTC to rat brain synaptosome activates Trk-dependent signaling, which mimics the 
action of their natural neurotrophic ligands [102,103]. TTC-mediated stimulation of Trk receptor in 
cultured cortical neurons and cerebellar granule neurons from rat [104] leads to activation PI-3K/Akt 
survival pathway as evidenced by fast and dose-dependent phosphorylation of Akt and its downstream 
target glycogen synthase kinase 3β (GSK3β). Additionally, TTC activated MAPK/ERK pathway as 
evidenced by phosphorylation of MAPK/ERK itself, two of its upstream kinases and downstream 
targets ribosomal protein S6 kinase (Rsk/S6K) and cAMP response element protein (CREB). Specific 
inhibition of Trk or PI-3K inhibited activation of both pathways by TTC. Additionally, TTC protects Toxins 2010, 2  
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cerebellar granule neurons from apoptotic death induced by low extracellular potassium [104], as 
evidenced by largely preserved mitochondrial function, decreased nuclear fragmentation and reduced 
activation of pro-caspase 3. Again, the effects on apoptosis were dependent on activated PI-3K/Akt 
and MAPK/ERK pathways. Although detailed mechanism on how TTC activates Trk receptor remains 
to be elucidated, it is likely to bear similarities to those of growth factors, and it is conceivable that Akt 
and MAPK/ERK activation by TTC enhances its endocytosis by the neurons. Phosphorylated 
MAPK/ERK, as well as neurotrophin receptor p75NTR, TrkB, NGF and BDNF, has also been shown 
to be present in TTC positive organelles during retroaxonal transport [26,105]. 
The evidence pointing towards antiapoptotic properties of TTC is not only limited to in vitro studies. 
Parkinson’s disease is caused by degeneration of nigrostriatal dopaminergic neurons which results in 
dopamine deficiency and clinical features involving slowness of movements, tremor and rigidity. 
Parkinsonism can be induced in experimental animals by 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), whose metabolite MPP
+ specifically destroys dopaminergic neurons. In cerebellar granule 
neurons in vitro, TTC protects against MPP
+ by enhanced protection against apoptosis [106]. In a rat 
model of Parkinsonism, where striatal lesions have been chemically induced in vivo by MPP
+, striatal 
administration of TTC before MPP
+ infusion resulted in significant amelioration of motor deficits and 
restored the dopamine levels to those of controls [107]. These results are promising because they may 
offer an alternative to the otherwise effective neurotrophins such as GDNF, which have poor 
penetration through BBB. Given that early diagnosis of Parkinson’s disease will be facilitated in the 
future by novel diagnostic markers, TTC administration could serve as an early intervention while a 
significant number of dopaminergic neurons remain healthy. 
Neuronal death after ischemia, a condition that temporarily deprives the brain of oxygen and 
glucose, has been shown to rely on similar mechanisms observed in ALS patients including glutamate 
mediated excitotoxicity and oxidative stress.
 Similarly, cardiac surgery may lead to severe oxidative 
stress
 due to the formation of oxidation products generated during ischemia
 and reperfusion [108]. In a 
model of cerebral ischemia in Mongolian gerbils, pre-treatment with intramuscular administration of 
TTC, by non-viral naked-DNA method, protected neurons by reducing ischemia-induced oxidative 
stress markers such as nitric oxide, superoxide, lipid peroxidation. Additionally, although TTC per se 
had no effect on motor response, it suppressed characteristic hyperlocomotion in the post-ischemic 
animal [109]. Therefore, TTC administration may serve as a promising candidate to treat post-ischemic 
neuronal damage or as a preventive treatment before ischemia-inducing operations such as 
cardiopulmonary bypass surgery.  
4. Future Directions 
The evidence above infers that TTC-based methods may serve as promising alternatives to viral 
gene delivery for neuronal gene therapy. However, before these therapies are applicable to humans, 
problems related to efficient delivery methods and potential immunogenicity of TTC need to be 
addressed. Additionally, there is a demand for optimization of the non-viral naked DNA method to 
increase expression levels which, at the moment, may not be sufficient for administration to large 
muscles (although this has been shown to be effective in mice). Finally, in future TTC-mediated Toxins 2010, 2  
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neuronal gene therapy experiments, it is crucial to include careful controls to investigate the potential 
TTC-specific or synergistic effects with the passenger molecules. 
Although clear benefits of TTC conjugation for efficient and specific neuronal targeting have been 
demonstrated, it is becoming clear that, the optimal organization of the fusion modules needs to be 
determined for each molecule. Genetic fusion of trophic factors or enzymes to the TTC may alter their 
conformation thus undermining the natural properties, for example, by blocking their active site by 
steric hindrance. Alternatively, the efficiency of the TTC to promote retrograde transport could be 
affected by the passenger molecule resulting in insufficient internalization or altered trafficking. For 
example, with different domain organizations of SOD1-TTC, the activity of the enzyme was affected 
but the internalization and transport in the neurons was not [52]. In contrast, the internalization of  
Bcl-xL-TTC depended on c-terminal location of the TTC domain [72]. Furthermore, the internalization 
of SMN1-TTC, but not its neuronal binding, seemed to be inhibited by the SMN1 itself, revealing that 
not all proteins may be suitable for TTC-mediated neuronal uptake [63]. Finally, co-administration of 
neurotrophic factors such as BDNF seems to enhance internalization of TTC by the motor neuron 
terminals [99]. Therefore, to ensure maximal efficiency, it would be advisable to address in vitro 
internalization and transport kinetics as well as activity of the passenger molecule before in vivo 
animal studies. 
The question of how much the passenger protein may influence the intracellular location remains, 
because the internalized TTC is largely endosomal. TTC-containing retrograde organelles display a 
neutral pH [25] which protects their cargo from degradation and allows long-distance axonal transport. 
Because this compartment is shared by neurotrophins and their receptors [105], diseases where 
neurotrophic stimulation is likely to alleviate pathology would be expected to benefit from TTC-fusion 
in a most straightforward manner. In contrast, if naturally cytosolic passenger molecules are bound to 
the membranes or trapped within endosomal compartment they may be ineffective even if their activity 
per se is maintained. SOD1 is normally cytosolic, and its vesicular location (as is the case with 
SOD1-TTC) may prevent its efficient function in free radical defence [53]. The situation may be even 
more complicated when trans-membrane transport is required to target the passenger molecule to a 
specific subcellular location, such as to the nucleus, mitochondria or lysosomes. In this case, at least 
partial delivery of TTC-HEXA to the secondary lysosomes is suggested by its capability to reduce the 
accumulated lysosomal substrates in the cortical cell cultures of feline TSD model [48]; whereas 
neuroprotective effects of Bcl-xL-TTC [72] may indicate mitochondrial targeting. Although this 
evidence is indirect, it may suggest that natural subcellular location of the passenger molecule can 
influence the route of TTC by diverting it from its normal transneuronal transfer pathway. If the 
release of the passenger molecule from the endosomal compartment is regarded important it may be 
facilitated by a fusion with a membrane translocating domain, such as that of diphtheria toxin [63,109]. 
Therefore, detailed studies of factors that facilitate routes to specific subcellular compartments 
(endosomal, lysosomal, mitochondrial, cytoplasmic or nuclear) are warranted. 
TTC is truly neurotropic in vitro and in vivo, when delivered as protein or naked-DNA using 
various administration routes. However, membrane binding and internalization of TeNT holotoxin is 
more efficient than that of TTC alone [111]. Design of modified TTC-based carrier proteins containing 
additional non-toxic molecular domains may enhance its neurotropic properties and, therefore, the 
ability to efficiently deliver therapeutic proteins to the neurons. On the other hand, translation of Toxins 2010, 2  
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TTC-mediated therapy to the clinical practice may be hindered due to immunogenic reactions towards 
TTC [112]. Most individuals in the developed world are vaccinated against tetanus, and even for those 
that are not, treatments in humans are expected to be long term when natural immunogenicity of TTC 
may become a problem. However, uptake of TTC by nerve terminals from an intramuscular depot is 
rapid and is not blocked by immunization against tetanus toxoid in mice [113]. Rapid neural 
internalization may protect TTC and conjugated passenger molecules by making them inaccessible to 
the antibodies. In fact, it has been suggested that circulating antibodies may even facilitate the 
specificity of the TTC-administration by inactivating molecules that potentially escape neuronal 
intake [114]. Additionally, modified ganglioside-binding domains of TTC that lack immunodominant 
epitopes may serve as an alternative strategy to circumvent TTC immunogenicity [115] (see also 
Dobrenis et al., 2009 – Abstract 38 at Lysosomal Disease Network World Symposium 2010) provided 
that these re-designed TTC-molecules retain their neurotropic and retrograde transport properties.  
Although rapid axonal transfer of TTC to the CNS, especially in the large-diameter fibers, has been 
demonstrated [46,116], for the treatment of neurological disorders in humans it may be more critical to 
address the methods of administration that result in sufficient and pertinent expression of the 
therapeutic molecules in all or most neurons affected by the disease. It is evident that when balancing 
the efficient production and safe, non-invasive administration on one hand, and sufficient expression 
level and duration on the other, both TTC-mediated and viral delivery methods in their current state 
require further development.  
Because TTC is able to stimulate signaling pathways that increase neuronal survival, the question 
remains of how much the reported effects in general can be ascribed to the passenger molecules and 
how much to the TTC-carrier itself. As proposed by Mendieta and coworkers [107], the antiapoptotic 
effect of TTC-Bcl-xL could be at least partially due to TTC carrier and not the cargo. The same applies 
with all studies where TTC alone was not used as a negative control, particularly those that 
demonstrate activation of neuronal survival pathways. It is also necessary to recognize the fact that not 
all studies that included “TTC alone” control report enhancement on neuronal survival signaling or 
TTC-dependent effects in disease models [79-81,95,96]. Therefore, it is feasible that TTC-dependent 
promotion of neuronal survival depends on variables such as cell types used for in vitro activation of 
signaling pathways, as well as route and dose of administration in vivo, which may differ between 
laboratories. In future studies, it is advisable to include TTC itself as a control to preclude its effect 
from those of putative therapeutic molecules. 
Another, perhaps related question is: Does the stimulation of retrograde transport per se contribute 
to the potential therapeutic properties of TTC? Defects in retrograde transport may characterize many 
neurodegenerative diseases [45,117,118] and experimentally induced defects in this cellular process 
replicate key features of human neurodegenerative pathology [27,119]. Therefore, stimulation of 
retrograde machinery may be beneficial in some conditions. Recent advances in molecular level live 
tracking techniques [120] may facilitate studies of the retrograde transport-stimulating actions of TTC 
and TTC-conjugates. 
Finally, TTC may serve to target non-proteinous molecules, such as DNA or drugs, specifically to 
neurons. TTC-conjugated nanoparticles made from biodegradable polymers can selectively target 
neuroblastoma cells as opposed to liver or endothelial cells in vitro [121]. Similarly, self-assembled 
ternary vectors consisting of poly (ethylene imine) and TTC protein have been used to target DNA Toxins 2010, 2  
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plasmids to dorsal root ganglion neurons in vitro, where they can elicit the expression of 
plasmid-encoded gene [122]. If shown to function in vivo, these vectors have a substantial potential to 
serve as retrograde transport-exploiting drug/gene delivery vehicles that may reduce the potential 
hazards associated with systemic drug delivery. 
5. Conclusions 
TTC offers a promising tool for specific targeting of neurons. It can be used either as a 
neuroanatomical and functional tracer, or administered directly by protein injection or by non-viral 
naked-DNA methods, to carry therapeutic biological activity into the CNS. Growing evidence suggests 
that TTC may itself harbor neuroprotective properties, which opens attractive avenues for future 
research on its potential use to alleviate neurological disorders. Future modifications of TTC molecule, 
as well as development of TTC-based therapeutic interventions, are likely to further enhance its 
efficacy and applicability as a molecular neurotrophic courier. 
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